Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Zinbryta (daclizumab beta) - Important Safety Information from Biogen as approved by the HPRA (March 2018)
Notice type:
3rd Party Publications
Date:
13/03/2018
Problem Or Issue:
Important Safety Information communication from Biogen: Zinbryta (daclizumab beta) - Marketing authorisation suspended in the European Union.
Important Safety Information - Zinbryta (daclizumab beta)
« Back
Date Printed: 26/04/2024